ERBB2 and invasive carcinoma: In one study in particular [23], accuracy was high in most comparisons (87.4% for the differentiation between invasive and non-invasive carcinoma, 100% triple-negative vs. triple-positive, 82.1% triple-negative vs. HR+, 97.2% HER+/HR+ vs. HER2-/HR+, 90% G1 vs. G2/G3 for invasive carcinoma, 100% G1 vs. G2/G3 for non-invasive carcinoma).